Article

FDA approves IOL for cataracts and presbyopia

Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D).

Huenenberg, Switzerland

-Alcon Inc. has received FDA approval for a lens designed for implantation during cataract surgery in patients with presbyopia (AcrySof IQ ReSTOR +3.0 D). The lens was introduced outside of the United States in 2008.

“The . . . IOL gives my patients a more comfortable reading distance, improved intermediate vision for tasks such as computer work, and excellent distance vision,” said one study investigator, Kerry Solomon, MD, who is professor of ophthalmology, Medical University of South Carolina, Charleston, and medical director, Storm Eye Institute, Mount Pleasant, SC.

The U.S. clinical trials included a 3-month follow-up exam of near, intermediate, and distance visual acuities. The percentage of patients in whom 20/20 or better vision was achieved at all three distances with the lens was nearly fourfold the rate of patients who received the control lens (AcrySof IQ ReSTOR +4.0 D), according to the company. The clinical studies also demonstrated a high rate of patient satisfaction, with more than 95% of patients stating that they would have the lens implanted again, Alcon relayed.

“Advanced-technology IOLs that correct for presbyopia and astigmatism are the fastest-growing IOL segment of cataract surgery,” said Kevin Buehler, senior vice president, global markets, and chief marketing officer, Alcon. “The addition of this new lens meets a growing desire on the part of cataract patients for spectacle independence after cataract surgery.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.